Non-Alcoholic Steatohepatitis (NASH)
Experts in the development and management of all aspects of NASH clinical trials
As a global leader in NASH and hepatology research, ICON delivers clinical expertise, experience, data and best practices to drive your program forward.
Our experts partner with sponsors, investigators, patients, and other collaborators to deliver strategic, data-driven solutions for NASH and hepatology studies.
ICON NASH, hepatology and viral hepatitis experience in the last 5 years:
-
172
Studies conducted -
35,000+
Patients and healthy volunteers -
6,900
Sites worldwide
Our clinical trial experience includes over 63 NASH studies, including 12 phase III NASH trials. In addition, we have supported clinical research in a range of indications, including:
- Cholestasis
- Cirrhosis
- Fatty liver disease
- Hepatic encephalopathy
- Hepatobiliary disease or hepatic impairment, (non-specified)
- Liver disease (other)
- Liver impairment / failure
- Liver transplant
- Non-alcoholic steatohepatitis (NASH)
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC)
- Veno-occlusive disease
Our team is built of MDs, statisticians, regulatory scientists, DPDs, PMs, CTMs, and CRAs with hepatology-specific expertise who understand these complex patient populations and study protocols.
This experience, combined with our data capabilities and global infrastructure, provides clients with greater access to patients, advanced imaging support and overall advancement of hepatology research.
Patient-centric approach
We are motivated in our daily work by the patients these treatments help, and we work to make clinical trial participation as convenient as possible for patients worldwide. We’ve crafted a superior patient journey, increasing access for potential participants, reducing the burden of participation, and enabling a truly patient-first experience throughout the entire development journey. Our protocols consider a patient’s daily life and standard of care and are free from unnecessary burdens and nuances. Building patient-focused studies not only helps patients who are enrolled but ultimately leads to faster approvals and widespread availability for all hepatology patients.
Webinar: Digital solutions to alleviate NASH clinical trial challenges
Attend our webinar to discover how digital technologies including MRI, MRE and whole slide imaging are helping to address NASH clinical trial challenges.
Webinar: Helping NASH study sites to succeed
How can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? Register for the on-demand webinar.
